Iris Energy Limited vs Viatris Inc — how do they compare? Iris Energy Limited trades at $35.27 (market cap $14.07B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while Iris Energy Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iris Energy Limited for 28 Days and Viatris Inc for 57 Days on average.
| IREN | VTRS | |
|---|---|---|
Market Cap | $14.07B | $20.03B |
Volume | 54,492,460 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $76.41 | $18.27 |
52-Week Low | $29.31 | $9.74 |
Typical Hold Time | 28 Days | 57 Days |
Enterprise Value | $16.02B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
IREN shares are trading at $35.19, down 9.05% in the last 24 hours, reflecting ongoing investor concerns despite strong analyst optimism. The stock shows bearish technical signals with key support at $33, while fundamental metrics reveal a challenging profitability picture with a negative net income margin of -99.38% despite revenue growth projections. Recent news highlights the company's aggressive pivot from Bitcoin mining to AI infrastructure, backed by multi-billion dollar contracts with Microsoft and NVIDIA.
The investment case hinges on execution of IREN's ambitious AI infrastructure expansion, with JPMorgan projecting $24 billion in annual revenue by 2030. However, significant risks include ballooning losses, high capital expenditure requirements, and intense competition in the neocloud space. Despite 80% analyst buy ratings and an $81 consensus price target suggesting 130% upside, the stock faces near-term pressure from missed earnings and negative cash flow trends.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Iris Energy is a next-generation data center company that powers Bitcoin mining and AI workloads using 100% renewable energy. It focuses on building sustainable infrastructure for the global digital economy.
Read more on IREN →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →